Johnson & Johnson (JNJ) : Fil Ltd reduced its stake in Johnson & Johnson by 4.09% during the most recent quarter end. The investment management company now holds a total of 4,753,300 shares of Johnson & Johnson which is valued at $585,701,626 after selling 202,514 shares in Johnson & Johnson , the firm said in a disclosure report filed with the SEC on Aug 11, 2016.Johnson & Johnson makes up approximately 1.78% of Fil Ltd’s portfolio.
Other Hedge Funds, Including , Foyston Gordon Payne Inc reduced its stake in JNJ by selling 7,240 shares or 3.06% in the most recent quarter. The Hedge Fund company now holds 229,608 shares of JNJ which is valued at $28,292,298. Johnson & Johnson makes up approx 4.98% of Foyston Gordon Payne Inc’s portfolio.Everett Harris Co Ca reduced its stake in JNJ by selling 2,855 shares or 0.3% in the most recent quarter. The Hedge Fund company now holds 949,387 shares of JNJ which is valued at $117,629,049. Johnson & Johnson makes up approx 4.09% of Everett Harris Co Ca’s portfolio.Ausdal Financial Partners reduced its stake in JNJ by selling 1,216 shares or 8.98% in the most recent quarter. The Hedge Fund company now holds 12,330 shares of JNJ which is valued at $1,544,086. Johnson & Johnson makes up approx 0.77% of Ausdal Financial Partners’s portfolio.Saratoga Research Investment Management reduced its stake in JNJ by selling 2,733 shares or 0.89% in the most recent quarter. The Hedge Fund company now holds 303,026 shares of JNJ which is valued at $37,947,946. Johnson & Johnson makes up approx 3.28% of Saratoga Research Investment Management’s portfolio.Farmers Merchants Investments Inc reduced its stake in JNJ by selling 1,887 shares or 1.34% in the most recent quarter. The Hedge Fund company now holds 138,721 shares of JNJ which is valued at $17,359,546. Johnson & Johnson makes up approx 1.87% of Farmers Merchants Investments Inc’s portfolio.
Johnson & Johnson opened for trading at $119.67 and hit $119.96 on the upside on Tuesday, eventually ending the session at $119.44, with a gain of 0.26% or 0.31 points. The heightened volatility saw the trading volume jump to 56,03,177 shares. Company has a market cap of $326,773 M.
On the company’s financial health, Johnson & Johnson reported $1.74 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 19, 2016. Analyst had a consensus of $1.68. The company had revenue of $18482.00 million for the quarter, compared to analysts expectations of $17985.80 million. The company’s revenue was up 3.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.71 EPS.
Many Wall Street Analysts have commented on Johnson & Johnson. Company shares were Reiterated by UBS on Jul 20, 2016 to “Buy”, Firm has raised the Price Target to $ 137 from a previous price target of $126 .Company shares were Reiterated by RBC Capital Mkts on Jul 20, 2016 to “Outperform”, Firm has raised the Price Target to $ 133 from a previous price target of $125 .Standpoint Research Initiated Johnson & Johnson on May 20, 2016 to “Sell”, Price Target of the shares are set at $94.
Johnson & Johnson is a holding company. The Company is engaged in the research and development manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Companys primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Companys research facilities are located in the United States Belgium Brazil Canada China France Germany India Israel Japan the Netherlands Singapore Switzerland and the United Kingdom.